Related Experiment Videos
CD56+ lymphoma with skin involvement: clinicopathologic features and classification
Robert Gniadecki1, Kristian Rossen, Elisabeth Ralfkier
1Departments of Dermatology and Pathology, Bispebjerg Hospital, Copenhagen, Denmark. rg01@bbh.hosp.dk
Archives of Dermatology
|April 21, 2004
Summary
CD56(+) lymphomas with skin involvement are rare, aggressive cancers with a median survival of 14 months. Older age and systemic spread are poor prognostic factors, with no effective treatments identified.
Area of Science:
- Hematology
- Oncology
- Dermatology
Background:
- Extranodal lymphomas expressing CD56 (neuronal cell adhesion molecule) often involve the skin and have a poor prognosis.
- Limited data exists on the clinicopathologic features and survival outcomes for CD56(+) lymphomas with cutaneous involvement.
Purpose of the Study:
- To investigate survival rates and prognostic factors in extranodal CD56(+) lymphomas presenting with skin involvement.
- To characterize the clinicopathologic features of these rare lymphomas.
Main Methods:
- A retrospective analysis of 181 patients with CD56(+) lymphoma involving the skin, including literature review and new case studies.
- Evaluation of survival data based on prognostic factors such as staging, histology, immune markers, and treatment modality.
Main Results:
- Three subtypes were identified: blastic, nasal-type NK/T-cell, and subcutaneous panniculitis-like lymphoma.
- Median survival was 14 months, with risk factors including age >55, systemic dissemination, and lack of CD30/CD4 expression.
- Forty-five percent of patients presented with purely cutaneous disease, but aggressive behavior was consistent across subtypes.
Conclusions:
- CD56(+) lymphomas with skin involvement are rare, aggressive hematologic malignancies with poor outcomes.
- No consistently effective treatments were identified, and older patients with CD30(-)CD4(-) lymphomas face increased mortality risk.